** Shares of drug developer Sage Therapeutics SAGE.O rise 5.6% to $7.49
** SAGE says it has rejected Biogen's BIIB.O $469 mln acquisition offer
** BIIB on Jan. 10 sent letter to SAGE CEO offering to buy all outstanding shares of co it does not already own for $7.22 per share
** SAGE says proposal "significantly undervalues Sage and believes it is not in the best interest of shareholders"
** SAGE says it is exploring alternatives
** BIIB, which is SAGE's largest shareholder, currently owns 10.2%, or over 6.24 mln shares, of SAGE's common stock
** SAGE fell ~76% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.